Moreover, no pathogenic TP53 mutations were identified in the analyzed set (0/17), which compared to prevalent cancers (7/21, 33.3% [38]) yielded a significantly lower TP53 mutation frequency in incident CRCs (p = 0.0108, Figure 3A,B, Supplementary Table S4). Here, TP53 is linked to cancer.